1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Zoetis Inc.

Zoetis Inc.

ZTS
Zoetis Inc.US flagNew York Stock Exchange
79.44
USD
-0.08
- -
33.30BMarket Cap
Zoetis Inc.
ZTS
(New York Stock Exchange)

Recent

price

79.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.49
8.85
8.67
9.12
9.55
9.54
9.86
10.83
12.06
13.09
14.04
16.39
17.23
18.53
20.38
21.35
21.76
Revenue per Share
0.23
0.51
0.87
1.01
1.16
0.68
1.66
1.76
2.96
3.14
3.44
4.29
4.51
5.08
5.47
6.03
6.05
Basic EPS, GAAP
0.27
0.76
0.66
0.99
0.86
0.88
1
2.75
3.71
3.75
4.47
4.67
4.08
5.1
6.5
6.55
6.38
Free Cash Flow per Basic Share
0.43
0.87
0.13
0.2
0.29
0.34
0.38
0.42
0.5
0.66
0.8
1
1.3
1.5
1.73
2
2.03
Dividend per Share
- -
- -
- -
0.56
1.42
1.76
2.99
4.32
6.78
9.27
11.91
15.16
18.5
22.33
26.36
31.01
32.46
Book Value per Share
3.11
3.8
4.38
-1.65
-0.73
-3.11
-2.44
-2.03
-4.93
-3.71
-1.33
0.82
0.59
1.94
2.02
-0.98
-1.15
Tangible Book Value per Share
478
478
500
500
501
500
496
490
483
478
476
474
469
461
454
443
437
Basic Weighted Avg Shares
3,582
4,233
4,336
4,561
4,785
4,765
4,888
5,307
5,825
6,260
6,675
7,776
8,080
8,544
9,256
9,467
9,509
Sales/Revenue/Turnover
8.01
14.93
19.14
17.98
20.25
22.46
28.58
32.5
32.29
32.24
33.99
36.05
36.24
35.92
36.65
38
37.57
Operating Margin (%)
185
205
200
209
204
199
240
242
308
412
441
448
465
491
497
487
487
Depreciation Expense
110
245
436
504
583
339
821
864
1,428
1,500
1,638
2,037
2,114
2,344
2,486
2,673
2,643
Net Income, GAAP
37.64
37.06
38.59
27.1
28.41
37.8
33.31
43.48
15.74
16.71
18.04
18.25
20.52
20.3
20.33
20.45
20.1
Effective Tax Rate (%)
3.07
5.79
10.06
11.05
12.18
7.11
16.8
16.28
24.52
23.96
24.54
26.2
26.16
27.43
26.86
28.23
27.79
Profit Margin (%)
1,308
1,468
1,741
1,942
2,379
2,049
2,273
3,123
3,176
2,942
4,441
5,133
4,339
4,454
2,574
4,533
4,421
Working Capital
673
575
509
3,642
3,624
4,463
4,468
4,953
6,443
6,111
6,758
6,743
6,738
6,752
5,394
9,238
9,238
LT Debt
3,344
3,736
4,041
962
1,337
1,091
1,499
1,786
2,185
2,708
3,773
4,544
4,403
4,991
4,770
3,331
3,233
Total Equity
8.83
9.52
11.45
12.95
14.47
12.16
15.53
15.26
20.55
18.69
18.15
20.4
19.44
19.99
23.07
23.56
23.53
Return on Invested Capital (%)
37.15
40.65
76.61
25.78
15.91
8.21
15.91
14.79
19.1
16.23
15.2
16.49
14.94
15.02
14.85
13.67
13.28
Return on Capital (%)
- -
- -
- -
358.72
117.19
42.51
69.49
48.05
53
38.93
32.45
31.69
26.65
24.71
22.32
20.78
19.9
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
7,069
9,042
9,045
LT Finance Leases
204
196
193
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
441
425
420
Market Capitalization
65,336
55,795
51,667

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,583
6,768
6,474
Cash, Cash Equivalents & STI
2,080
2,310
1,940
Accounts Receivable, Net
1,541
1,590
1,506
Inventories
2,465
2,430
2,550
Total Current Liabilities
1,807
2,235
2,053
Payables & Accruals
1,371
1,718
1,693
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.82%
-0.78%
-30.17%
Free Cash Flow
27.29%
7.48%
-1.66%
Net Income, GAAP
27.95%
10.52%
7.52%
Sales/Revenue/Turnover
7.18%
7.35%
2.28%
Total Cash Common Dividend
18.32%
18.72%
13.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,190
2,361
2,388
2,317
9,256
2025
2,198
2,460
2,400
2,387
9,467
2026
2,262
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.31
1.37
1.51
1.29
5.47
2025
1.34
1.61
1.63
1.38
6.03
2026
1.42
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.43
0.43
0.43
1.73
2025
0.5
0.5
0.5
0.5
2
2026
0.53
- -
- -
- -
- -
Similar Companies
Marksans Pharma Limited (MARKSANS.NS)
Sanofi India Limited (SANOFI.NS)
GlaxoSmithKline plc (GSK.SW)
Impact Therap-b (7630.HK)
Oscotec Inc. (039200.KQ)
Bristol-Myers Squibb Company (0R1F.L)
Business
Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.

Company News

APIChat

  • gurufocus.com

    INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • prnewswire.com

    INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • seekingalpha.com

    5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (June 2026)

  • globenewswire.com

    DEADLINE ALERT for CALX, AVAV, ZTS: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • globenewswire.com

    DEADLINE ALERT for AVAV, CALX, ZTS, and LCID: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  • globenewswire.com

    ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • globenewswire.com

    ZTS Deadline Alert: The Gross Law Firm Reminds Zoetis Inc. (ZTS) Investors of Securities Class Action Deadline on July 27, 2026

  • newsfilecorp.com

    ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

  • globenewswire.com

    ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

  • globenewswire.com

    ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

  • prnewswire.com

    ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

  • gurufocus.com

    Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • feeds.newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • prnewswire.com

    Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  • globenewswire.com

    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zoetis Inc. (ZTS)

  • businesswire.com

    Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future

  • gurufocus.com

    INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • businesswire.com

    INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • newsfilecorp.com

    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS